Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘More Money’ Could Move To OTC Monograph Process

This article was originally published in The Tan Sheet

Executive Summary

CDER Director Woodcock is “trying to figure out ways … to get more money into” FDA’s OTC monograph work.

You may also be interested in...



FDA Adds OTC Monograph Staff By Shifting CDER Appropriations

CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.

FDA Adds OTC Monograph Staff By Shifting CDER Appropriations

CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel